Home > Pulmonology > New asthma guidelines advise single maintenance and reliever therapy

New asthma guidelines advise single maintenance and reliever therapy

Journal
JAMA
Reuters Health - 07/12/2020 - In its first asthma guideline update in more than a decade, the U.S. National Heart, Lung, and Blood Institute (NHLBI) recommends "SMART" therapy - a single inhaler containing both an inhaled corticosteroid (ICS) and the long-acting bronchodilator formoterol - for moderate-to-severe persistent asthma, among other guidance aimed mainly at primary care physicians. "This ICS-formoterol combination therapy is recommended for both daily and when needed therapy in people with moderate-to-severe persistent asthma," Dr. Michelle Cloutier of UCONN Health in Farmington told Reuters Health by email. "This treatment approach not only improves asthma outcomes, including reducing asthma exacerbations, but it also achieves these positive outcomes at a reduced total exposure to corticosteroids." "One area of controversy that the 2020 Updates appears to have resolved is the often-used practice of increasing the dose of an ICS during an asthma exacerbati...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on